Drug Costs

Commonwealth Fund Blog Series on Medicaid Drug Pricing Issues

Congress and the Biden Administration are currently pursuing substantial drug pricing reforms as part of the reconciliation legislation expected to move this fall.  While the focus is primarily on Medicare, Medicaid should not be overlooked. In an ongoing series of posts for the Commonwealth Fund’s To the Point blog, I examine some key Medicaid drug […]

New CBO Study Compares Net Prices for Brand-Name Drugs Among Federal Programs, Finds Medicaid Gets Largest Discounts

In a new groundbreaking study, the Congressional Budget Office compared brand-name drug prices, net of rebates and discounts, across select federal programs and agencies including Medicaid, Medicare Part D and the Department of Veterans Affairs (VA).  It found that Medicaid gets the lowest net prices, far below that of Medicare Part D plans and well […]

House Energy and Commerce Committee Reconciliation Legislation Includes Sound Medicaid Drug Rebate Provision

Last night, the House Energy and Commerce Committee unveiled its recommendations for the House COVID-19 relief reconciliation bill, with a markup scheduled for February 11, 2021.  One sound Medicaid provision would, as of January 1, 2023, eliminate the current cap on total drug rebates that manufacturers must pay state Medicaid programs, which would produce significant […]

State-imported drugs would not affect 340B drug prices

Modern Healthcare By: Rachel Cohrs Drugs imported by states under the Trump administration’s importation plan will not be subject to Medicaid rebates, which means they would not set new 340B prices according to CMS guidance released Friday… The savings from drug importation would hinge on how low states could get drug prices and how widely […]